EDITORIAL


https://doi.org/10.5005/jp-journals-10071-23468
Indian Journal of Critical Care Medicine
Volume 24 | Issue 6 | Year 2020

Pediatric Scrub Typhus: A Commentary


Soonu Udani

Department of Critical Care, SRCC Children’s Hospital, Mumbai, Maharashtra, India

Corresponding Author: Soonu Udani, Department of Critical Care, SRCC Children’s Hospital, Mumbai, Maharashtra, India, Phone: +91 9820999310, e-mail: drsudani@gmail.com

How to cite this article Udani S. Pediatric Scrub Typhus: A Commentary. Indian J Crit Care Med 2020;24(6):380.

Source of support: Nil

Conflict of interest: None

ABSTRACT

The commentary is to highlight not the profile of scrub typhus but the correlation of serology with immunofluorescence.

Keywords: Epidemiology, Immunofluorescence, Scrub typhus.

Scrub typhus has been reported from all over the world, but is endemic in the “Tsutsugamushi Triangle,” a geographical region of South and East Asia and the Southwest Pacific. In India, the first case reports appeared from Himachal Pradesh in the 1970s and 1980s but the major literature seemed to come from the southern states.1

The practice of using tetracyclines and chloramphenicol in outpatient and general practice clinics, coupled with the widespread use of pesticides like DDT, may have masked the presentation of the disease to tertiary care centers and there appeared to be a “decline” in the incidence.2 A resurgence was seen after about two decades in the winter months, which are post monsoon in the north as well as the southern regions of India.

Mortality, which varies considerably from known data but is about 8–10% under 30 years of age, as also seen in a review3 of 2,261 cases, was similar in this study. Hence, there were no other marked new or distinguishing aspects in this study in terms of clinical features or treatment.

However, this study4 did show good correlation of the IgM ELISA with the microimmunofluorescence as well as with the PCR. Diagnostic challenges remain as PCR-based techniques are not available outside of major centers, especially in areas where they are probably needed the most and hence the recommendation to treat on a “syndromic” basis in endemic areas based on undifferentiated fever, thrombocytopenia, or rash. This leads to overdiagnosis and overtreatment lending to the cycle of antibiotic resistance in the community. Microimmunofluorescence, the gold standard so far, is also unavailable but ELISA-based serology is easily available and accessible.

The reliability of the ELISA IgM validated here by the authors helps in reinforcing this as a good test in helping the clinician to narrow the treatment. As otherwise, these patients get empirically and unnecessarily treated for malaria, typhoid fever, and encephalitis often with artemether, multiple antibiotics, and acyclovir for prolonged periods.

REFERENCES

1. Varghese GM, Mathai E, Manjula J, Joseph N. Scrub typhus: prevalence and diagnostic issues in rural Southern India Rita Isaac. Clin Infect Dis 2004;39(9):1395–1396. DOI: 10.1086/424748.

2. Chunchanur SK. Scrub typhus in India-an impending threat!. Ann Clin Immunol Microbiol 2018;1(1):1003.

3. Taylor AJ, Paris DH, Newton PN. A systematic review of mortality from untreated scrub. Negl Trop Dise 2015;9(8): e0003971. DOI: 10.1371/journal.pntd.0003971.

4. Nallasamy K, Gupta S, Bansal A, Biswal M, Jayashree M, Zaman K, et al. Clinical profile and predictors of intensive care unit admission in pediatric scrub typhus: a retrospective observational study from North India. Indian J Crit Care Med 2020;24(6):445–450.

________________________
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.